Compare Global Payments Inc (GPN) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global Payments Inc vs Merck & Co., Inc. — how do they compare? Global Payments Inc trades at $79.28 (market cap $21.40B), while Merck & Co., Inc. trades at $127.06 (market cap $305.29B). The key difference: Merck & Co., Inc. is far larger — about 14.3× Global Payments Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.75%). Which is the better fit depends on your goals.
| GPN | MRK | |
|---|---|---|
Market Cap | $21.40B | $305.29B |
Sector | Industrials | Health |
52-Week High | $90.01 | $129.52 |
52-Week Low | $62.47 | $77.60 |
Enterprise Value | $39.11B | $348.71B |
Dividend Yield | 1.28% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Global Payments (GPN) trades at $75.89, down 1.25% today, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. The company maintains solid cash flow generation ($2.66B operating cash flow in 2025) and recently announced a $0.25 dividend. Despite negative net income margin and ROE, revenue trends show recovery potential with 2026 projections at $8.9B. Analyst consensus remains positive with 58% buy ratings and $81.56 price target.
GPN presents a mixed outlook with strong operational execution offset by profitability challenges. The Worldpay integration and AI-powered POS expansion offer growth catalysts, but margin pressure and rising debt levels pose risks. Current valuation at 28.76 P/E appears reasonable given the company's market position in payment technology, though investors should monitor competitive pressures in the fintech space.
Merck (MRK) trades at $120.80, down 2.6% on the day, with technical indicators showing a bullish moving average signal but neutral oscillators. The company reported strong recent earnings beats and maintains solid profitability with a 73.91% gross margin and 13.59% net margin. Recent news highlights Merck's acquisition of Terns Pharmaceuticals for approximately $6.7 billion to bolster its oncology pipeline, while institutional investors continue accumulating shares.
The outlook remains positive with analyst consensus at Buy (67.57%) and a $137.30 price target, suggesting 13.7% upside. Key risks include integration challenges from the Terns acquisition, competitive pressures in oncology, and potential regulatory headwinds. Strong cash flow generation ($16.47B operating cash flow in 2025) supports continued dividend payments and strategic investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global Payments Inc
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
